Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...
Aptose Biosciences is a clinical-stage biotechn...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.